Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Use the CMS fee schedule search tool to pull the exact rate for your MAC locality
Consultations and care are provided exclusively by experienced, qualified medical professionals
The LEADER trial 28 (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) studied a 1.8-mg dose in more than 9,000 patients with type 2 diabetes and found the incidence of acute pancreatitis was similar between the liraglutide and placebo groups (0.4% vs 0.5%, respectively)
Beyond pancreatic and hepatic biology, tirzepatide is increasingly studied in central nervous system models
